Dactylitis News and Research

RSS

Dactylytis is a fusiform swelling of an entire finger or toe.

New insights into the exacerbation of psoriasis through specific genetic defects

The inflammatory potential of tissue-resident regulatory T cells in a murine gain of function model.

27 Mar 2024

Relaxation of pandemic measures resulted in the surge of Strep A infections to above pre-COVID levels

New research from France shows that infections cause by Group A Streptococcus (GAS) fell by 80% as the first COVID lockdown took effect in March 2020 and stayed at low levels until March 2022, from which point they increased by 18% a month to rise well above pre-COVID levels.

17 Apr 2023

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.

13 May 2011

Predictors for sickle-cell-anemia complications

Researchers at UT Southwestern Medical Center have determined that the level, or saturation, of oxygen in blood could be used to identify children with sickle cell anemia who are at an increased risk of stroke.

6 Mar 2008

Researchers investigate predictors for sickle-cell-anemia complications

1 Mar 2008

Stroke risk for sickle cell children with early complications

Children with sickle cell disease who experienced major complications such as pain and lung disease early in life are at no greater risk for stroke or death during later childhood, new research from UT Southwestern Medical Center shows.

30 Jan 2007

Remicade receives European approval for treatment of psoriatic arthritis

Schering-Plough Corporation today announced that the European Commission has approved the use of Remicade (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.

26 Jul 2006

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

In this trial, REMICADE provided a 70 percent improvement (as measured by ACR 70) in symptoms of arthritis in nearly one-third of patients, compared with only 2 percent of patients on placebo at 24 weeks.

10 Jun 2004